Dual HER2 Blockade Superior to Single Blockade for HER2+/HR+ Breast Cancer

Dual HER2 blockade was superior to single blockade in postmenopausal women with HER2-positive, HR-positive metastatic breast cancer.

Source: CancerNetwork - June 8, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Breast Cancer News Source Type: news